Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 6 July 2026, driven primarily by a shift in technical indicators. Despite this improvement, the company continues to face significant fundamental headwinds, including operating losses and weak long-term growth prospects, which keep the overall outlook cautious.

Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 30 June 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s micro-cap status, weak long-term growth, and unfavourable technical trends have prompted a reassessment of its investment appeal.

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 June 2026, driven primarily by a shift in technical indicators despite ongoing fundamental weaknesses. The micro-cap pharmaceutical and biotechnology company’s Mojo Score rose to 34.0, reflecting a cautious optimism among market analysts amid mixed financial and valuation signals.

A sharp decline of 13.14% in a single session has dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.52 on 10 Jun 2026, marking a significant underperformance against its sector and the broader market.

A sharp decline of 8.84% today dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.65, extending its downward trajectory despite recent positive quarterly results. This drop comes amid broader market weakness, with the Sensex also falling sharply, but the stock’s underperformance remains pronounced.

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 June 2026. This adjustment reflects deteriorating technical indicators, persistent operating losses, and underwhelming long-term financial trends despite recent positive quarterly results.

A sustained decline has pushed Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.74 on 29 May 2026, marking a 28.4% drop over the past year and signalling continued pressure on this micro-cap pharmaceutical stock despite some recent positive financial results.

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026, driven primarily by a shift in technical indicators amid persistent fundamental weaknesses. While the company’s financial trend shows some positive quarterly results, its long-term fundamentals and valuation metrics continue to weigh on investor sentiment, resulting in a cautious outlook.

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. This revision reflects deteriorating technical indicators, persistent operating losses, and weak long-term fundamentals despite recent positive quarterly financial results.

Vivanza Biosciences Ltd., the Gujarat-based pharmaceutical company with a market capitalisation of ₹8.00 crores, reported a troubling quarter-on-quarter deterioration in Q4 FY26, swinging to a net loss of ₹0.45 crores from a profit of ₹0.20 crores in the previous quarter. The 325.00% decline in profitability overshadowed an otherwise impressive year-on-year revenue growth trajectory, raising serious concerns about operational efficiency and cost management at the micro-cap pharmaceutical player.

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in price attractiveness despite ongoing operational challenges and a tough market backdrop.

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite ongoing challenges reflected in its negative returns and profitability metrics, the stock’s current price-to-earnings and price-to-book value ratios suggest a more compelling entry point compared to peers and historical averages.

Vivanza Biosciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade, despite ongoing challenges in profitability and returns. This change, driven primarily by a sharp correction in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.